Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial-Reference-Cited by-同舟云学术

Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial

Published:2017-08 Issue:8 Volume:18 Page:1104-1115
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Harrington Kevin J,Ferris Robert L,Blumenschein George,Colevas A Dimitrios,Fayette Jérôme,Licitra Lisa,Kasper Stefan,Even Caroline,Vokes Everett E,Worden Francis,Saba Nabil F,Kiyota Naomi,Haddad Robert,Tahara Makoto,Grünwald Viktor,Shaw James W,Monga Manish,Lynch Mark,Taylor Fiona,DeRosa Michael,Morrissey Laura,Cocks Kim,Gillison Maura L,Guigay Joël

Publisher

Elsevier BV

Subject

Oncology

Reference42 articles.

1. Individualised quality of life as a measure to guide treatment choices in squamous cell carcinoma of the head and neck;Licitra;Oral Oncol,2016

2. Head and neck cancer: historical evolution of treatment and patient self-care requirements;Sobecki-Ryniak;Clin J Oncol Nurs,2013

3. Body image in patients with head and neck cancer: a review of the literature;Rhoten;Oral Oncol,2013

4. Predictors of emotional distress in patients with head and neck cancer;Singer;Head Neck,2012

5. An open-label single-arm, phase II trial of zalutumumab, a human monoclonal anti-EGFR antibody, in patients with platinum-refractory squamous cell carcinoma of the head and neck;Saloura;Cancer Chemother Pharmacol,2014

Cited by 347 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Catalysts of change: Immunotherapy's frontier in oral oncology;Oral Oncology Reports;2024-09

2. Locoregional therapies combined with immune checkpoint inhibitors for liver metastases;Cancer Cell International;2024-08-31

3. Prolonged in-use physicochemical and biological stability of nivolumab and pembrolizumab diluted in saline infusion bags and in partially used medication vials;Journal of Oncology Pharmacy Practice;2024-08-30

4. Preoperative prediction of pathologic response to neoadjuvant immunotherapy in resectable locally advanced head and neck squamous cell carcinoma using multiparametric MRI;Chinese Journal of Academic Radiology;2024-08-08

5. Deciphering the interplay of HPV infection, MHC-II expression, and CXCL13+ CD4+ T cell activation in oropharyngeal cancer: implications for immunotherapy;Cancer Immunology, Immunotherapy;2024-08-06